1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Analysis of BioMarin Pharmaceuticals

Analysis of BioMarin Pharmaceuticals

  • January 2014
  • -
  • Aruvian's R'search
  • -
  • 105 pages

BioMarin Pharmaceutical Inc. manufactures and markets biopharmaceuticals for many sever diseases and medical conditions. The company has many approved products along with several investigational product candidates. BioMarin markets its products to specialty pharmacies, pharmaceutical wholesalers in Europe, the US as well as Latin America. The company also retails through distributors and hospitals.

Aruvian’s R’search presents Analysis of BioMarin Pharmaceutical. A complete and comprehensive analysis of BioMarin Pharmaceutical, includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.

Company analysis from Aruvian includes a history of BioMarin Pharmaceutical, a business segment analysis of the segments BioMarin Pharmaceutical operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company’s major competitors.

A financial analysis of BioMarin Pharmaceutical is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.

A SWOT Framework Analysis of BioMarin Pharmaceutical completes this in-depth company analysis.

Table Of Contents

Analysis of BioMarin Pharmaceuticals
A. Executive Summary

B. Looking at the Industry
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impacts on the Industry
B.4 Challenges Facing the Industry
B.5 Future Perspective

C. Industry PEST Framework Analysis
C.1 Political Aspects
C.2 Economic Aspects
C.3 Social Aspects
C.4 Technological Aspects

D. Looking at BioMarin Pharmaceutical
D.1 Company Profile
D.2 History of the Company
D.3 Ownership Pattern in the Company
D.3.1 Major Holders
D.3.2 Major Direct Holders
D.3.3 Top Institutional Holders
D.3.4 Top Mutual Fund Holders
D.4 Organizational Divisions
D.5 Profiling the Key Executives
D.6 Products and Services

E. Looking at Business
E.1 Business Segments
E.2 Geographical Segments
E.3 Company Subsidiaries

F. BioMarin Pharmaceutical: SWOT Framework Analysis
F.1 Strengths to Build Upon
F.2 Weaknesses to Overcome
F.3 Opportunities to Exploit
F.4 Threats to Overcome

G. Profiling the Competition
G.1 BioSpecifics Technologies Corp
G.1.1 Corporate Profile
G.1.2 Business Segment Analysis
G.1.3 Financial Analysis
G.1.4 SWOT Analysis
G.2 Enzon Pharmaceuticals Inc
G.2.1 Corporate Profile
G.2.2 Business Segment Analysis
G.2.3 Financial Analysis
G.2.4 SWOT Analysis
G.3 Biogen Idec Inc
G.3.1 Corporate Profile
G.3.2 Business Segment Analysis
G.3.3 Financial Analysis
G.3.4 SWOT Analysis

H. BioMarin: Financial Analysis
H.1 Current Financials
H.2 Balance Sheet
H.3 Profit and Loss Statement
H.4 Ratio Analysis
H.4.1 Capital Market Ratios
H.4.2 Annual Ratios
H.4.3 Quarterly Ratios

I. BioMarin Pharmaceutical: Future Perspective

J. Glossary of Terms




Companies Mentioned

BioSpecifics Technologies Corp
Enzon Pharmaceuticals Inc
Biogen Idec Inc
BioMarin Pharmaceutical

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

  • $ 6995
  • Industry report
  • January 2017
  • by GBI Research

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation Summary Melanoma is a type of cancer that begins in the ...

North America Vision Care Market Outlook to 2022

North America Vision Care Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by GlobalData

North America Vision Care Market Outlook to 2022 Summary GlobalData’s new report, "North America Vision Care Market Outlook to 2022", provides key market data on the North America Vision Care market. ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.